Formation Biologics
Bristol Myers Squibb Enters Agreement to Acquire Forbius
TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio.
TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ...
Read more
Formation Biologics Recognized As One of the Most Promising Life Science Companies by Rice Alliance
(May 31, 2016) – Formation Biologics was recognized as one of the Rice Alliance 10 Most Promising Life Science Companies at the 2016 Texas Life Science Forum hosted by the Rice Alliance for Technology and Entrepreneurship, BioHouston, and Texas Healthcare and BioScience Institute. The companies were chosen by industry experts and investors.
The event is one of the largest life science venture capital conferences in the Southwest and featured more than 40 industry and investment speakers. Among more than 600 attendees were ...
Read more
Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
Read more
AvidBiologics and National Research Council of Canada to collaborate on antibody-drug conjugates
Toronto-based AvidBiologics Inc., a leading Canadian biotech company, and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs).
Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.
"The work performed by NRC is crucial to assembling the data package ...
Read more
MaRS Innovation joins new financing round for AvidBiologics Inc.
TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).
Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors.
This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.
Today's financing builds on prior ...
Read more